MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 17, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate
Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growth SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Primmune Therapeutics, Inc., a biotech company harnessing the power of the innate immune system, today announced the appointment of Andrew Sharabi, M.D., Ph.D., as Chief Medical Officer and Chris Krueger, J.D., as Executive Chairman of its Board of Directors. Additionally, Primmune revealed the formation of its Melanoma Clinical Study Advisory Board to support the clinical development of PRTX007, a novel orally administered, systemically acting, small molecule toll-like receptor 7 (TLR7) agonist as an immunotherapy for solid tumors. “We are thrilled to welcome Dr. Sharabi as Chief Medical Officer. He brings a rare combination of clinical expertise in melanoma, head